{"title":"Breast surgical site infections in patients undergoing lumpectomy with and without closure of defect.","authors":"Emily Palmquist, Risa Kiernan, Varadan Sevilimedu, Tiana Le, Monica Morrow, Mahmoud El-Tamer","doi":"10.1007/s10549-025-07819-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Postoperative infection rates in the United States following breast cancer surgery, including mastectomy with or without reconstruction, range from 2-26%. Management of post-lumpectomy defects may involve simple skin closure or oncoplastic closure; however, the effect of defect repair on postoperative infection rates has not been well documented. Here we determine how oncoplastic closure of partial mastectomy defects affects postoperative infection rates and antibiotic use.</p><p><strong>Methods: </strong>In this retrospective single-institution study, patients undergoing lumpectomy with and without oncoplastic closure of defect were included between 2018-2020. Clinicopathologic/treatment data were collected from medical records. Patients receiving antibiotics on postoperative days 5-30 were reviewed to confirm wound infection. Associations between demographic and clinicopathologic factors and postoperative infections were analyzed.</p><p><strong>Results: </strong>3937 patients met eligibility criteria; 2273 (58%) had oncoplastic closure. The overall postoperative wound infection rate (includes cellulitis) was 8.4% (332), and true surgical site infection, as defined by the CDC (excludes cellulitis), was seen in 70 (1.8%) patients. On univariate analysis, age ≥ 60 years, diabetes, hypertension, and BMI ≥ 30 were associated with increased breast infection. Oncoplastic closure was protective against postoperative breast infections (odds ratio [OR]0.70, p = 0.040). On multivariable analysis oncoplastic closure had marginally decreased breast infection rates (OR 0.71, p = 0.053); however, this was not significant. BMI ≥ 30 was the only risk factor that remained a significant predictor of increased breast infection rates (OR1.63, p = 0.021).</p><p><strong>Conclusions: </strong>Oncoplastic closure of lumpectomy defects had marginally significant lower rates of postoperative breast infections. As oncoplastic techniques are increasingly adopted in breast-conserving surgery, it is important to further study the protective nature of lumpectomy defect closure to reduce postoperative infection rates.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07819-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Postoperative infection rates in the United States following breast cancer surgery, including mastectomy with or without reconstruction, range from 2-26%. Management of post-lumpectomy defects may involve simple skin closure or oncoplastic closure; however, the effect of defect repair on postoperative infection rates has not been well documented. Here we determine how oncoplastic closure of partial mastectomy defects affects postoperative infection rates and antibiotic use.
Methods: In this retrospective single-institution study, patients undergoing lumpectomy with and without oncoplastic closure of defect were included between 2018-2020. Clinicopathologic/treatment data were collected from medical records. Patients receiving antibiotics on postoperative days 5-30 were reviewed to confirm wound infection. Associations between demographic and clinicopathologic factors and postoperative infections were analyzed.
Results: 3937 patients met eligibility criteria; 2273 (58%) had oncoplastic closure. The overall postoperative wound infection rate (includes cellulitis) was 8.4% (332), and true surgical site infection, as defined by the CDC (excludes cellulitis), was seen in 70 (1.8%) patients. On univariate analysis, age ≥ 60 years, diabetes, hypertension, and BMI ≥ 30 were associated with increased breast infection. Oncoplastic closure was protective against postoperative breast infections (odds ratio [OR]0.70, p = 0.040). On multivariable analysis oncoplastic closure had marginally decreased breast infection rates (OR 0.71, p = 0.053); however, this was not significant. BMI ≥ 30 was the only risk factor that remained a significant predictor of increased breast infection rates (OR1.63, p = 0.021).
Conclusions: Oncoplastic closure of lumpectomy defects had marginally significant lower rates of postoperative breast infections. As oncoplastic techniques are increasingly adopted in breast-conserving surgery, it is important to further study the protective nature of lumpectomy defect closure to reduce postoperative infection rates.
目的:美国乳腺癌手术后的感染率,包括乳房切除术合并或不合并重建,范围为2-26%。乳房肿瘤切除术后缺陷的处理可能包括简单的皮肤闭合或肿瘤整形闭合;然而,缺损修复对术后感染率的影响并没有很好的文献记载。在这里,我们确定乳房部分切除缺陷的肿瘤肿瘤闭合如何影响术后感染率和抗生素的使用。方法:在这项回顾性的单机构研究中,纳入了2018-2020年期间接受乳房肿瘤切除术的患者,伴有或不伴有肿瘤肿瘤缺损闭合。临床病理/治疗数据从医疗记录中收集。术后5-30天接受抗生素治疗的患者复查以确认伤口感染。分析人口统计学和临床病理因素与术后感染之间的关系。结果:3937例患者符合入选标准;2273例(58%)有肿瘤增生闭合。总体术后伤口感染率(包括蜂窝织炎)为8.4%(332例),CDC定义的真正手术部位感染(不包括蜂窝织炎)为70例(1.8%)。单因素分析显示,年龄≥60岁、糖尿病、高血压和BMI≥30与乳房感染增加有关。肿瘤整形闭合对术后乳房感染有保护作用(优势比[OR]0.70, p = 0.040)。在多变量分析中,肿瘤肿瘤闭合略微降低了乳房感染率(OR 0.71, p = 0.053);然而,这并不显著。BMI≥30是唯一仍能显著预测乳房感染率增加的危险因素(OR1.63, p = 0.021)。结论:乳房肿瘤切除缺陷的肿瘤整形闭合术后乳房感染的发生率明显降低。随着保乳手术越来越多地采用肿瘤整形技术,进一步研究乳房肿瘤切除缺陷闭合的保护性质以降低术后感染率具有重要意义。
期刊介绍:
Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.